So-called checkpoint proteins on immune cells serve as gatekeepers that are supposed to keep foreign invaders from entering healthy cells. Certain cancers use these checkpoints to avoid detection.

The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option for patients. The subcutaneous form of Keytruda showed to deliver the same ...

Sue McCarthy shares her experience overcoming stage 3B lung cancer, reflecting on the impact of her diagnosis. After ...

In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...

Doctors are experimenting with using lower doses of blockbuster cancer drugs. It could help hundreds of thousands of lives — if pharmaceutical companies would allow it.

A subcutaneously injected version of Merck cancer immunotherapy Keytruda is now FDA approved, a regulatory decision that gives patients a less burdensome dosing option and provides the pharmaceutical ...

Merck has obtained the Food and Drug Administration’s permission for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and ...

The FDA has approved a new injectable version of cancer drug Keytruda as Merck seeks to protect its market dominance. Here are five things to know: The approved shot is Keytruda Qlex, a widely used ...